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correlated with TS location 13.8% vs 24.8% and 1.7% versus 
5.8% in case of non-TS and TS (p < 0.05). 21/25 of patients 
with severe DES were in TS or temporal location. No patient 
had enucleation for DES. On MVA, diameter (hazard ratio 
HR:1.103, CI95:1.042-1.169, p 0.001), tumor volume 
(HR:0.0696, CI95:0.486-0.996, p=0.048, % of ciliary body in 
the 90% isodose line (HR:1.014, CI95:1.003-1.026, p=0.015), 
gel compensator (HR:0.717, CI95:0.535-0.960, p=0.025) and 
TS location (HR:2.581, CI95:1.695-3.929, p<0.001) were 
significantly associated with the occurrence of DES. 
 
Conclusion: Although the incidence of DES and severe DES 
was increased in TS melanomas and this correlated with the 
dose to the lacrimal gland, their characteristics were less 
favorable (larger, superior involvement of ciliary body and 
limbus). Occurrence of severe DES in TS but also temporal 
locations suggests that involvement of the ciliary arteries 
may also be responsible for severe DES. The correlation of TS 
with ciliary involvement suggests that limbus cells may 
participate in the occurrence of DES. The role of palpebral 
and corneal irradiation will be further investigated. Since DES 
is manageable, TS location should not be considered a 
contraindication for protontherapy. 
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Purpose or Objective: In parapapillary melanoma patients, 
radiation-induced optic complications are frequent and visual 
acuity is often compromised. We investigated dose effect 
relationships for the optic nerve with respect to visual acuity 
after protontherapy. 
 
Material and Methods: of 5205 patients treated between 
1991 and 2014, those treated between 1994 and 2013 (using 
CT-based planning) to 52 Gy in four fractions, minimal 6 
month follow-up and documented initial and last visual 
acuity, were included. Deterioration of ≥ 0.3 logMAR between 
initial and last visual acuity was reported. 
 
Results: 865 consecutive patients were included. Median 
follow-up was 69 months, mean age 61.7 years, tumor 
abutted the papilla in 64.9% and tumor to fovea distance was 
≤ 3 mm in 74.2% of patients. Five-year relapse-free survival 
rate was 92.7%. Initially, 72.6% of patients had ≥ 20/200 
visual acuity, 47.2% had ≥ 20/200 at last follow -up. A wedge 
filter was used in 47.8% of the patients, with a positive 
impact on vision and no impact on relapse. Glaucoma, 
radiation-induced optic neuropathy, maculopathy were 
reported in 17.9%. 47.5%, and 33.6%, respectively. Patients 
irradiated to ≥ 80% of their papilla had better visual acuity 
when limiting the 50% (30 Gy) and 20% (12 Gy) isodoses to ≤ 2 
mm and 6 mm of optic nerve length, respectively. 
 
Conclusion: A personalized protontherapy plan can be used 
efficiently with good oncologic and functional results in 
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Purpose or Objective: To estimate the toxicity and efficacy 
of carbon ion radiotherapy for adenoid cystic carcinomas 
(ACC) invading the skull base. 
 
Material and Methods: Between April 1997 and August 2013, 
a total of 193 patients with ACC of the head-and-neck were 
treated with carbon ion radiotherapy. All of these patients 
had neither regional lymph node nor distant metastasis 
before carbon ion radiotherapy. The prescribed tumor doses 
were 57.6 or 64.0 Gy (RBE) in 16 fractions over four weeks. 
Of the 193 patients, 78 patients with ACC invading the skull 
base were analyzed. There were 37 males and 41 females. 
The median age was 52 years (range, 23-75 years). The most 
common primary site was the parenasal sinus (46%), followed 
by the nasopharynx (13%), the nasal cavity (10%) and the hard 
palate (10%). The extent of surgery was biopsy alone in 52 
patients (67%), partial resection in 5 patients (6%). Twenty of 
78 patients (27%) had recurrence tumors after surgery. 
Median follow-up time was 52 months (range, 10-177.7 
months). Patients were divided into two groups according to 
intracranial involvement; Group A was made up of 32 
patients whose tumors invading the cranial fossa, Group B 
consisted of 46 patients whose tumors invading the 
intracranial region or cerebra. Acute and late morbidities 
were evaluated by the RTOG, the RTOG/ EORTC and the 
CTCAE (version 4.0). 
 
Results: The 5-year local control and overall survival rates of 
all patients were 65 % and 60 %, respectively. Median survival 
time was 74.4 months. In total 45 patients died, the major 
cause of death was distant metastases (67%). The 5-year local 
control rates were 71% for Group A and 56% for Group B. The 
5-year overall survival rates were 74% for Group A and 49% 
for Group B. In univariate analysis using log-rank test, there 
were no significant differences in local control and overall 
survival rates between the two groups. There was no 
evidence of any unexpected severe acute (grade ≥4) and late 
(grade ≥3) reactions to the skin, the mucosa and other 
critical organs. In regard to brain toxicity, 5 of 32 patients 
(16%) in Group A and 9 of 42 patients (21%) in Group B 
developed grade 2 late reactions, which necessitated steroid 
administration temporarily. Four patients in Group B who had 
marginal recurrence received re-irradiation. Therefore, it 
was difficult to evaluate brain toxicity for these patients. 
 
Conclusion: Our results showed acceptable brain toxicities 
and excellent therapeutic effectiveness for unresectable 
adenoid cystic carcinomas invading the skull base. 
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Purpose or Objective: Proton beam therapy (PT) has 
experienced increasing interest over time especially in 
pediatric malignancies as PT offers a chance to reduce post-
treatment late effects. The West German Proton Therapy 
Center Essen (WPE) started treatments for pediatric tumors 
in June 2013. Since September 2013 all children under the 
age of 18 years were enrolled in the standardized prospective 
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registry study for children (“KiProReg”) at WPE. Initial 
findings are presented. 
 
Material and Methods: Between September 2013 and 
September 2015, data on 138 children (78 males, 60 females, 
aged 0.9-17.9 years (median 5.7 years)) were prospectively 
collected in KiProReg at WPE. Diagnoses were CNS tumours 
(n=73), sarcomas (n=59), extracranial germ cell tumors (n=3) 
and others (n=3), respectively. Treatment sites were brain 
(n=72), head and neck including base of skull (n=38), spine 
(n=15), or pelvis (n=13). In 73.9% of the patients, 
macroscopic residual disease was present before PT. The 
median total dose of PT was 54.0 Gy (range 29.8-74.0 Gy). 
Only two patients had a mixed beam technique. Due to the 
very young age, sedation was necessary in 55.1% of children. 
Concurrent chemotherapy was applied in 54.3% of children. 
Side-effects were classified according to Common 
Terminology Criteria for Adverse Events (CTCAE) V4.0 grading 
system. 
 
Results: Median follow-up (FU) since first diagnosis was 1.2 
years (range 0.3-16.3 years). PT was well tolerated. No or 
only mild to moderate acute side-effects (grade 1 to 2) were 
documented in the majority of children (n=116). During PT, 
acute grade 3 side-effects were observed for blood/bone 
marrow (n=21), gastrointestinum (n=8) or as general disorders 
(n=3) as well as anorexia (n=1) when compared to baseline. 
Acute grade 4 side-effects during PT were only seen for 
blood/bone marrow (n=9). In 77 children, information on 
toxicity three months after PT is available. Only few patients 
presented with grade 3 or 4 toxicities, predominantly for 
blood/bone marrow (grade 3 n=7, grade 4 n=2). Seven of 
them had received chemotherapy after PT. So far, 17 
patients failed due to recurrence or progression (local n=5; 
systemic n=12). Six of them (4.3%) have died so far, all due 
to disease. 
 
Conclusion: Initial prospective data from WPE registry 
suggest good feasibility with only mild or moderate side-
effects in the majority of children even when administering 
high doses at critical sites. Higher-grade side-effects primary 
for blood and bone marrow are obviously influenced by 
concurrent chemotherapy. Early local control rates achieved 
with PT are promising so far. However, longer FU is needed 
to analyze long-term outcome and late effects. 
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Purpose or Objective: To report clinical outcomes for 
patients treated with image-guided proton therapy for 
localized prostate cancer. 
 
Material and Methods: Under institutional review board 
approval, the medical records of 1,215 men enrolled either 
on a prospective protocol or an outcomes tracking study 
treated for localized prostate cancer with proton therapy at 
our institution between 2006 and 2010 were reviewed. 
Ninety-eight percent of patients received 78 Gy (RBE) or 
higher; 15% received androgen deprivation therapy (ADT). 
Five-year freedom from biochemical progression (FFBP), 
distant metastasis-free survival, and cause-specific survival 
rates are reported for each risk group. Prospectively 
collected patient-reported quality-of-life data and high-grade 
toxicities are reported. A multivariate analysis was 
performed to identify clinical predictors of biochemical 
failure. 
 
Results: The median follow-up was 5.5 years. The 5-year 
FFBP rates were 99%, 94%, and 74% in low-, intermediate-, 
and high-risk patients, respectively. Actuarial 5-year rates of 
late grade 3 gastrointestinal and genitourinary toxicity were 
0.6% and 2.4%, respectively. Median International Prostate 
Symptom Scores (IPSS) before treatment and at >4 years 
after treatment were 7 and 7. Median changes in EPIC scores 
between baseline and 4+ years of follow-up were minimal in 
the bowel, urinary irritative/obstructive, and urinary 
incontinence summary domains. 
 
Conclusion: Image-guided proton therapy provided excellent 
biochemical control rates for patients with localized prostate 
cancer. Patient-reported quality of life outcomes are 
favorable and actuarial rates of high-grade toxicity were low 
following proton therapy. 
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Purpose or Objective: Reirradiation of non resectable local 
recurrence, after previous full course of radiotherapy, is 
extremely challenging. Particle therapy may theoretically be 
the ideal tool for re-irradiation thanks to its complete sparing 
of large volumes of non target tissues already irradiated to 
low-medium dose with conformal X-ray based techniques. We 
report CNAO experience, in terms of acute toxicity and early 
response to hadrontherapy, in patients with head and neck, 
skull-base and sacral local relapse, re-irradiated with carbon 
ions or protons. 
 
Material and Methods: Since February 2013 to February 
2015, 70 patients ( M/F = 41/29) underwent hadrontherapy in 
CNAO as re-irradiation. Site of disease was head and neck in 
52 patients cancer, sacrum in 12 patients, skull – base in 4 
patients and brain in 2 cases. The histologies were: squamous 
cell carcinoma ( 21 pts), adenoid cystic carcinoma (18 pts), 
chordoma (7 pts), other sarcoma (6 pts), adenocarcinoma (7 
pts), meningioma ( 4 pts), others (7 pts). Sixty-two patients 
had been treated with Carbon Ions, the rest (8 pts) with 
protons. Average age was 59 ( range 31 – 78). Previous 
radiotherapy doses ranged between 54 to 76 Gy ( with 
conventional fractionation) and 20 to 28 Gy ( with 
hypofractionation). Mean prescription dose was 61.7 Gy [RBE] 
( 32.5 – 64), mean dose per fraction was 2.4 Gy [RBE] ( 2 – 
4.5). Early toxicity was evaluated during, at the end and 
within 90 days after radiotherapy (RT). Patients were also 
followed up for late toxicity and radiologic response every 
three months after RT with magnetic resonance (MRI) and 
clinical evaluation.  
 
Results: Acute toxicity was mild with no G4 event. At the end 
of treatment 26 pts (37%) had G0 toxicity; 27 pts (38%) had 
G1 toxicity; 16 pts (23%) had G2 toxicity and only 1 pts (1%) 
had G3 mucositis. At three months this favorable profile was 
maintained; FU average 9 months ( range 3 – 24 ). Only one 
patient had G4 toxicity detected at 3 months (unilateral 
blindness due to intentional irradiation of one optic nerve 
beyond tolerance dose). Only 3 patients had G3 toxicity: skin 
fistula and osteoradionecrosis, 6 months after RT and 
cerebral edema ( requiring medical treatment) 9 months 
after RT. The patient with longest FU (24 months), has late 
toxicity G1 (hearing impairment). At the time of analysis 11 
patients had died of progressing disease (PD), 6 and 9 months 
progression free survival were 83% and 72% respectively. 
 
Conclusion: Hadrontherapy as reirradiation allows good dose 
distribution with optimal sparing of already irradiated organs 
at risk. Due to mild acute toxicity hadrontherapy may be 
considered safe and well tollerated. Longer follow up is 
needed to confirm the efficacy and the late side effects. 
 
